NCT07360392 BiFeS vs. iPACK in Postoperative Knee Arthroplasty Analgesia
| NCT ID | NCT07360392 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Amasya University |
| Condition | Arthroplasty, Replacement, Knee |
| Study Type | INTERVENTIONAL |
| Enrollment | 88 participants |
| Start Date | 2026-04-20 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 88 participants in total. It began in 2026-04-20 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Biceps Femoris Short Head (BiFeS) block is a new fascial plane block technique targeting the sensory innervation of the posterolateral capsule of the knee while preserving motor function. The aim of this study is to evaluate the postoperative analgesic efficacy of the BiFeS block combined with the adductor canal block (ACB) in patients undergoing total knee arthroplasty, compared to ACB + iPACK block. The study is planned as a prospective, randomized, double-blind, parallel two-group trial. Patients will be randomized in a 1:1 ratio to receive ACB + iPACK (Group A) or ACB + BiFeS (Group B). Postoperative pain scores (VAS), opioid consumption, early mobilization, and quality of recovery (QoR-15) outcomes will be compared.
Eligibility Criteria
Inclusion Criteria: * Scheduled for unilateral total knee arthroplasty * Classified as ASA physical status I-III Exclusion Criteria: * Scheduled for revision arthroplasty or bilateral surgery * Allergy to local anesthetics or contraindication to regional blocks * Neurological disorders, peripheral neuropathy, or conditions affecting lower extremity muscle strength * Coagulopathy or receiving anticoagulant therapy * History of severe liver, kidney, or heart failure * Chronic opioid use or history of substance abuse * Patients experiencing intraoperative complications (e.g., excessive bleeding) * Cases in which adequate sensory blockade is not achieved after the block
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07360392 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Arthroplasty, Replacement, Knee. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07360392 currently recruiting?
Yes, NCT07360392 is actively recruiting participants. Contact the research team at bulentmericcam@gmail.com for enrollment information.
Where is the NCT07360392 trial being conducted?
This trial is being conducted at Amasya, Turkey (Türkiye).
Who is sponsoring the NCT07360392 clinical trial?
NCT07360392 is sponsored by Amasya University. The trial plans to enroll 88 participants.